Pfizer’s breast cancer-fighter Ibrance posts stellar second-line survival data

Carly Helfand

Last month, Pfizer announced it had cut short its PALOMA-3 trial thanks to impressive second-line for new cancer-fighter . And now, industry-watchers have a glimpse into those data, announced Saturday at ASCO.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS